Agoracom: Small Cap Investment - Resverlogix Corp. - Pfizer's PCSK9 Inhibitor bococizumab

...We Welcome You To The Resverlogix HUB withIn The AGORACOM COMMUNITY!

Reply New Message

Prev Message Back To Forum Threaded View Next Message

masila

Rank: Vice President [?]

Points: 818 [?]

Votes: 16 Score: 3.7 [?]

Your Vote:

Please Log In to Vote

Did you know? You can earn activity points by filling your profile with information about yourself (what city you live in, your favorite team, blogs etc.)

Pfizer's PCSK9 Inhibitor bococizumab - further development being scrapped

posted on Nov 01, 2016 11:17AM

Based on this article, it seems PCSK9 might not be the greatest road to travel either.

Pfizer said bococizumab gradually lost its potency in reducing "bad" LDL cholesterol and caused more irritation at the injection site than similar recently approved drugs.

Also quite costly. Wonder if Amgen and Regeneron's drugs will see a similar fate.

https://ca.finance.yahoo.com/news/pfizer-quarterly-profit-falls-38-percent-110306205--finance.html

Maybe another reason to renew interest in the RVX approaches to improving CVD health.